1588 related articles for article (PubMed ID: 35894705)
21. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
[TBL] [Abstract][Full Text] [Related]
22. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
24. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
25. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
26. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
[TBL] [Abstract][Full Text] [Related]
27. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients.
Eren Sadioğlu R; Demir E; Evren E; Aktar M; Şafak S; Artan AS; Meşe S; Ağaçfidan A; Çınar G; Önel M; Karahan ZC; Şengül Ş; Keven K; Türkmen A
Transpl Infect Dis; 2021 Dec; 23(6):e13740. PubMed ID: 34606134
[TBL] [Abstract][Full Text] [Related]
28. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
[TBL] [Abstract][Full Text] [Related]
29. COVID-19 After Vaccination in Lung Transplant Recipients: Real-Life Data.
Türkkan S; Çelik Başaran F; Şahin MF; Beyoğlu MA; Yılmaz E; Yazıcıoğlu A; Yiğit Özay H; Bindal M; Tezer Tekçe Y; Yekeler E
Exp Clin Transplant; 2023 Mar; 21(3):265-271. PubMed ID: 35867010
[TBL] [Abstract][Full Text] [Related]
30. Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth.
Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Lahav Sher M; Barsha H; Shalabna E; Zolotarevsky A; Lavie O; Kedar R; Riskin-Mashiah S
Eur J Obstet Gynecol Reprod Biol; 2022 Jul; 274():148-154. PubMed ID: 35653903
[TBL] [Abstract][Full Text] [Related]
31. Coronavirus disease 2019 vaccine in pediatric post-kidney transplantation.
Ajlan AA; Aleid H; Ali T; DeVol E; Marquez KAH; Aldhaferi R; Karar EM; Mohammed AEI; Tiba M; Fajji L; Aldakhil H; Al-Awwami M; Almslam MS; Assiri A; Algoufi T; Broering DC
Clin Transplant; 2023 Jun; 37(6):e14983. PubMed ID: 37026809
[TBL] [Abstract][Full Text] [Related]
32. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
[TBL] [Abstract][Full Text] [Related]
33. Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort.
Bonazzetti C; Tazza B; Gibertoni D; Pasquini Z; Caroccia N; Fanì F; Fornaro G; Pascale R; Rinaldi M; Miani B; Gamberini C; Morelli MC; Tamé M; Busutti M; Comai G; Potena L; Borgese L; Salvaterra E; Lazzarotto T; Scudeller L; Viale P; Giannella M;
Clin Infect Dis; 2023 May; 76(10):1761-1767. PubMed ID: 36636955
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
Vargas-Herrera N; Fernández-Navarro M; Cabezudo NE; Soto-Becerra P; Solís-Sánchez G; Escobar-Agreda S; Silva-Valencia J; Pampa-Espinoza L; Bado-Pérez R; Solari L; Araujo-Castillo RV
PLoS One; 2022; 17(10):e0268419. PubMed ID: 36251630
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
36. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic.
Reischig T; Kacer M; Vlas T; Drenko P; Kielberger L; Machova J; Topolcan O; Kucera R; Kormunda S
Am J Transplant; 2022 Mar; 22(3):801-812. PubMed ID: 34860470
[TBL] [Abstract][Full Text] [Related]
37. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
38. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
[TBL] [Abstract][Full Text] [Related]
39. Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.
McAteer J; Kalluri DD; Abedon RR; Qin CX; Auerbach SR; Charnaya O; Danziger-Isakov LA; Ebel NH; Feldman AG; Hsu EK; Mohammad S; Perito ER; Thomas AM; Chiang TPY; Garonzik-Wang JM; Segev DL; Werbel WA; Mogul DB
Pediatr Transplant; 2024 Feb; 28(1):e14671. PubMed ID: 38317335
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
